Navigation Links
Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Date:9/18/2007

pon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... a condition that occurs when red blood cells are in ... has anemia, the body does not get enough oxygen, since ...
(Date:8/27/2014)... -- Kewaunee Scientific Corporation (Nasdaq: KEQU ) ... cash dividend by 9% to twelve cents per outstanding ... the dividend payable on September 22, 2014 to stockholders ... 8, 2014. About Kewaunee Scientific ... is a recognized global leader in the design, manufacture, ...
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014 /PRNewswire/ ... Co., Ltd, ("Menovo") today announced they had entered into ... primarily targeting the United States ... Menovo will jointly develop products for Amerigen to commercialize ... will be responsible for manufacturing API and finished product ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2
... The Halifax Health - Betty Jane France Center ... of a new decade of caring by unveiling a ... held this afternoon in Daytona Beach, Fla. ... will celebrate the 10th anniversary of Speediatrics. In recognition ...
... flu hospitalization rates for African-Americans, Hispanics, and American Indian/Alaska ... for Whites during the 2009-2010 flu season, according to ... the Trust for America,s Health (TFAH). At the same ... lower for African Americans and Hispanics than for Whites. ...
Cached Medicine Technology:Speediatrics Unit Celebrates 10th Anniversary 2Speediatrics Unit Celebrates 10th Anniversary 3New Report Finds H1N1 Hospitalization Rates Higher But Vaccination Rates Lower for Minorities 2New Report Finds H1N1 Hospitalization Rates Higher But Vaccination Rates Lower for Minorities 3New Report Finds H1N1 Hospitalization Rates Higher But Vaccination Rates Lower for Minorities 4
(Date:8/28/2014)... York (PRWEB) August 28, 2014 An unprecedented ... and neck issues, Cloud 9 Spine offers their resources online ... problems can quickly become a brick wall of discouragement as ... a professional opinion, Cloud 9 Spine offers a ... technology merged with human interaction that sets Cloud 9 Spine ...
(Date:8/28/2014)... 28, 2014 Top 10 Best ... hosting companies and announces Bluehost, HostMonster ( http://www.hostmonster.com/track/seohosts ... for the webmasters worldwide who want to buy ... As the world’s most popular server-side scripting language, ... other general-purpose programs. It is now installed on ...
(Date:8/28/2014)... Now in its 4th year, Step ... 2011 by two brain aneurysm survivors. The ongoing mission of ... education to help increase early detection and to help support ... aneurysm. We hope that you will be able to join ... 4th Annual Step for Hope Run/ Walk on Saturday, September ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
(Date:8/28/2014)... 28, 2014 The Pulmonica is a ... resonant, meditative sounds that can be felt vibrating in ... to use it – just taking long, slow, deep ... , Here are some examples of how to ... your eyes, relax, and maintain good posture. Try to ...
Breaking Medicine News(10 mins):Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2Health News:Step for Hope and Raise Brain Aneurysm Awareness 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:Ever Thought of Meditating With a Harmonica; Harmonica Techs, Inventors of the Pulmonica® Pulmonary Harmonica®, Present Tips on How to Relax with Soothing Sounds 2
... favor of drugs in the pipeline, review finds , ... of drug studies published in major medical journals answer ... available medications works best for a particular condition. , ... effectiveness" studies, where experts seek to determine which available ...
... more than 80,000 who gave one up shows procedure carries ... a kidney carries few health risks, with donors living just ... donate, the largest study to date of donors has found. ... who donated a kidney between 1994 and 2009, researchers found ...
... ... ... ... ...
... , ... ... ... ...
... ... ... ... ...
... a certain type of genetic susceptibility to lung cancer ... with even a small exposure to cigarette smoke, a ... Cincinnati (UC) has concluded. For family members who carry ... similar for both light and heavy smokers, the researchers ...
Cached Medicine News:Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 2Health News:Most Drug Studies Don't Help Docs Pick Best Treatment 3Health News:Kidney Donors Go On to Lead Long, Healthy Lives 2Health News:Kidney Donors Go On to Lead Long, Healthy Lives 3Health News:Introducing KePRO(TM) Engage Health - A Revolutionary Wellness & Lifestyle Management Company 2Health News:Introducing KePRO(TM) Engage Health - A Revolutionary Wellness & Lifestyle Management Company 3Health News:Introducing KePRO(TM) Engage Health - A Revolutionary Wellness & Lifestyle Management Company 4Health News:Introducing KePRO(TM) Engage Health - A Revolutionary Wellness & Lifestyle Management Company 5Health News:Online Tool Created to Contact Vatican Officials: 'Why Are American Bishops Allowed to Defy the Pope's Words Concerning Child Killing and the Eucharist?' 2Health News:Online Tool Created to Contact Vatican Officials: 'Why Are American Bishops Allowed to Defy the Pope's Words Concerning Child Killing and the Eucharist?' 3Health News:Online Tool Created to Contact Vatican Officials: 'Why Are American Bishops Allowed to Defy the Pope's Words Concerning Child Killing and the Eucharist?' 4Health News:Online Tool Created to Contact Vatican Officials: 'Why Are American Bishops Allowed to Defy the Pope's Words Concerning Child Killing and the Eucharist?' 5Health News:GoodTherapy.org and PsychCentral.com Partner to Help Therapy Seekers Find a Therapist 2Health News:GoodTherapy.org and PsychCentral.com Partner to Help Therapy Seekers Find a Therapist 3Health News:GoodTherapy.org and PsychCentral.com Partner to Help Therapy Seekers Find a Therapist 4Health News:GoodTherapy.org and PsychCentral.com Partner to Help Therapy Seekers Find a Therapist 5Health News:GoodTherapy.org and PsychCentral.com Partner to Help Therapy Seekers Find a Therapist 6Health News:Genetic variant greatly increases lung cancer risk for light smokers 2
... The SourceLink™ Delivery System offers a ... It addresses the challenges associated with ... provides the flexibility of seed and ... packaged per customers desired quantity and ...
... The Bard EXPRESS Seeding Cartridge System is ... delivering radioactive seeds and spacers into a ... Each cartridge has a(n): outer radiation safety ... synthetic absorbable spacers, integrally molded fitting that ...
... The Sysmex UF-100 is designed to ... microscopic analysis. It combines the superior ... automated urine sample analysis. Continuous sampling ... the rack-based autosamplers, streamlining sample processing in ...
... Q-Track II Holter Monitoring System uses technology ... the worlds first true 12-lead digital Holter ... of any beat contained in the 24-hour ... ,The preprocessing work done by the Q-12 ...
Medicine Products: